Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Tianjin Kingyork Pharmaceutical is a leading Chinese pharmaceutical company specializing in the development, production, and global distribution of steroid hormone APIs and finished dosage forms. As a core subsidiary of the Tianjin Kingyork Group, it operates one of the largest corticosteroid manufacturing bases in Asia and is a critical global supplier of essential medicines such as dexamethasone, prednisone, and hydrocortisone. The company's extensive portfolio includes tablets, sterile injectables, and topical preparations across therapeutic areas like endocrinology, dermatology, and cardiology. With multiple GMP certifications and a strong focus on international quality standards, Kingyork exports its products to over 40 countries and regions, including highly regulated markets in North America and Europe.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Tianjin Kingyork Pharmaceutical.